Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RTA 744 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A (RTA 744) | EXPERIMENTAL | Receive study drug for three consecutive days, Cycle repeated every 21 days. |
| Group C (RTA 744 Injection) | EXPERIMENTAL | Receive study drug once a week for four consecutive weeks. Repeat cycle every 5 weeks. |
| Name | Type | Description |
|---|---|---|
| RTA 744 | DRUG | Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml. |
| RTA 744 injection | DRUG | Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks. |
Inclusion Criteria: * Prior histologically confirmed anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligo-astrocytoma, glioblastoma multiforme, or gliosarcoma, for whom no other effective therapy is available. * A prior histologic diagnosis of a lower grade of glioma is allo...
RTA 744 is an investigational small molecule being developed for the treatment of glioma, a type of brain tumor. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in patients.
RTA 744 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting clinical trials to evaluate the safety and potential efficacy of this investigational drug in patients with recurrent high-grade gliomas.
RTA 744 is in Phase 1 clinical development. It is an investigational drug, meaning it is not yet approved by the FDA or other regulatory agencies. The Phase 1 trial is designed to assess the safety, tolerability, and dosing of the drug in patients with recurrent high-grade gliomas.
RTA 744 has been studied in one completed Phase 1 clinical trial with the identifier NCT00526812, titled 'A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas.' The trial enrolled 54 participants in the United States and included adults aged 18 years and older.
No, RTA 744 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial (NCT00526812) was a safety study in patients with recurrent high-grade gliomas, but the drug has not yet received regulatory approval for any indication.